Alzahrani Mazen, Kamal Yumna F, Akram Muhammad A
Ophthalmology, Jeddah Eye Hospital, Jeddah, SAU.
Medicine and Surgery, King Abdulaziz University, Jeddah, SAU.
Cureus. 2024 Jan 27;16(1):e53055. doi: 10.7759/cureus.53055. eCollection 2024 Jan.
Periorbital atopic dermatitis (AD) is a common sign in ophthalmological practice and usually has a persistent and relapsing course. Treatment with topical corticosteroids has various side effects associated with their usage. Tacrolimus topical ointment has unique immunomodulatory properties that decrease skin inflammation and pruritus in AD. In this case series, we present a prospective case series of five patients (three males and two females) who received topical application of tacrolimus ointment 0.1-0.03% in the periorbital area twice daily for one to four weeks. The pre- and post-treatment images of all patients were recorded to compare the effects of the treatment. The cases were selected from patients attending the outpatient clinics of East Jeddah Hospital, Saudi Arabia. All patients were suffering from AD. Patients underwent a clinical assessment by tactile inspection (location, size, color, and surface condition) in the first week, secondweek, third month, and first year. We may conclude from this study that tacrolimus showed promising outcomes and is safe and effective for the treatment of flares or resistant periorbital AD in both adults and children.
眶周特应性皮炎(AD)是眼科临床常见体征,通常呈持续性且易复发。外用糖皮质激素治疗存在多种与之相关的副作用。他克莫司软膏具有独特的免疫调节特性,可减轻AD患者的皮肤炎症和瘙痒。在本病例系列中,我们展示了一个前瞻性病例系列,共5例患者(3例男性,2例女性),他们在眶周区域每日两次外用0.1%-0.03%的他克莫司软膏,持续一至四周。记录所有患者治疗前后的图像以比较治疗效果。这些病例选自沙特阿拉伯吉达东部医院门诊的患者。所有患者均患有AD。患者在第一周、第二周、第三个月和第一年接受了通过触诊(部位、大小、颜色和表面状况)进行的临床评估。我们可以从这项研究得出结论,他克莫司对成人和儿童发作性或难治性眶周AD的治疗显示出良好的效果,且安全有效。